Cargando…

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We performed a prospective observational s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolter, P, Stefan, C, Decallonne, B, Dumez, H, Bex, M, Carmeliet, P, Schöffski, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527784/ https://www.ncbi.nlm.nih.gov/pubmed/18665181 http://dx.doi.org/10.1038/sj.bjc.6604497

Ejemplares similares

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Prospective Analysis of Risk for Hypothyroidism after Hemithyroidectomy
por: Beisa, Virgilijus, et al.
Publicado: (2015)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
por: Huygh, G., et al.
Publicado: (2006)

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
por: Shinohara, N, et al.
Publicado: (2011)

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
por: Awada, A. H., et al.
Publicado: (2012)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

The Influence of Prior Hyperthyroidism on Euthyroid Graves' Ophthalmopathy
por: Termote, Karolien, et al.
Publicado: (2014)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

High Prevalence of Associated Birth Defects in Congenital Hypothyroidism
por: Reddy, P. Amaresh, et al.
Publicado: (2010)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
por: Lewin, J, et al.
Publicado: (2014)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
por: Vasileiadis, Theofanis, et al.
Publicado: (2019)

Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
por: Shu, Mao, et al.
Publicado: (2016)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
por: Thompson Coon, J S, et al.
Publicado: (2009)

Frequency of Celiac Disease in Patients with Hypothyroidism
por: Mehrdad, Mojtaba, et al.
Publicado: (2012)

Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
por: Kilic, Nevin, et al.
Publicado: (2012)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
por: Novello, S, et al.
Publicado: (2009)

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
por: Wu, C, et al.
Publicado: (2015)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
por: Mateo, Joaquin, et al.
Publicado: (2016)

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
por: Buda-Nowak, Anna, et al.
Publicado: (2017)

Correction of Hypothyroidism Seems to Have No Effect on Body Fat
por: Bakiner, Okan, et al.
Publicado: (2013)

Association of Lipids with Oxidative Stress Biomarkers in Subclinical Hypothyroidism
por: Santi, Adriana, et al.
Publicado: (2012)

Prevalence of hypothyroidism in Japanese chronic kidney disease patients
por: Yuasa, Rena, et al.
Publicado: (2020)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Can Levothyroxine Be Taken as Evening Dose? Comparative Evaluation of Morning versus Evening Dose of Levothyroxine in Treatment of Hypothyroidism
por: Rajput, Rajesh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_q8fthk1nvu0m28ppb275pjs4b4